SPAS(SH:603168)2024-10-30 07:47Financial Performance - The company's operating revenue for Q3 2024 was ¥122,549,791.28, a decrease of 22.06% compared to the same period last year[2]. - The net profit attributable to shareholders for Q3 2024 was -¥6,038,443.65, representing a decline of 199.02% year-on-year[2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2024 was -¥25,143,210.86[3]. - The basic earnings per share for Q3 2024 was -¥0.01, a decrease of 200.00% year-on-year[3]. - The diluted earnings per share for Q3 2024 was also -¥0.01, reflecting the same decline as basic earnings[3]. - The net profit for the third quarter of 2024 was -28,400,706.00 RMB, compared to a net profit of 79,196,484.37 RMB in the same period of 2023, representing a significant decline[17]. - The total profit for the third quarter of 2024 was -22,988,834.03 RMB, down from 86,895,736.40 RMB in the previous year[17]. - The operating profit for the third quarter of 2024 was -21,306,927.13 RMB, compared to an operating profit of 74,785,970.83 RMB in the same period of 2023[17]. - The total comprehensive income for the third quarter of 2024 was -28,400,706.00 RMB, compared to 79,196,484.37 RMB in the same period of 2023[18]. - The basic and diluted earnings per share for the third quarter of 2024 were both -0.08 RMB, compared to 0.21 RMB in the same period of 2023[18]. Assets and Liabilities - The total assets at the end of the reporting period were ¥2,118,346,234.72, a decrease of 2.39% from the end of the previous year[3]. - The company's total assets as of the end of Q3 2024 were CNY 2,118,346,234.72, slightly down from CNY 2,170,297,153.91 at the end of Q3 2023[15]. - Total liabilities decreased to CNY 431,279,549.04 in Q3 2024 from CNY 440,922,801.81 in Q3 2023, showing a decline of about 2%[14]. - The total equity attributable to shareholders was CNY 1,685,014,557.54, down from CNY 1,719,676,896.42 in the previous year, indicating a decrease of approximately 2%[15]. Cash Flow - The net cash flow from operating activities for the year-to-date was ¥11,598,155.58[3]. - The cash flow from operating activities for the first three quarters of 2024 was 11,598,155.58 RMB, a recovery from a negative cash flow of -5,244,613.45 RMB in the same period of 2023[20]. - The net cash flow from investing activities for the first three quarters of 2024 was -188,693,982.51 RMB, compared to -246,219,043.97 RMB in the previous year[20]. - The net cash flow from financing activities for the first three quarters of 2024 was 16,888,567.98 RMB, down from 146,729,300.51 RMB in the same period of 2023[20]. - Cash and cash equivalents amount to approximately RMB 195.46 million, showing a decrease from RMB 355.67 million[12]. - The cash and cash equivalents at the end of the third quarter of 2024 were 195,459,449.81 RMB, down from 420,324,791.98 RMB at the end of the same period in 2023[21]. - The company's cash and cash equivalents decreased to CNY 401,044,387.38 from CNY 552,663,001.01, a decline of approximately 27%[13]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 31,175[8]. - The largest shareholder, Shanghai Yanghe Industrial Co., Ltd., holds 78,249,836 shares, accounting for 20.64% of total shares[8]. - The company has a total of 46,983,204 shares held by Chen Dekang, representing 12.39% of total shares[9]. - The top ten shareholders collectively hold a significant portion of the company's shares, with the first five alone accounting for over 45%[8]. Operational Insights - The company reported a significant decline in sales of eye drops and cephalosporins, contributing to the overall profit decrease[6]. - The company reported a cautious approach in project implementation, leading to a delay in investment progress[10]. - The company has adjusted the investment schedule for fundraising projects, extending the completion date to September 30, 2025[10]. - The actual controller's commitment to avoid competition has been extended by 36 months due to market conditions[11]. Expenses - Total operating costs for the first three quarters of 2024 were CNY 401,137,647.70, down from CNY 443,241,120.29 in 2023, indicating a reduction of about 9.5%[16]. - Research and development expenses for the first three quarters of 2024 amounted to CNY 44,765,811.58, compared to CNY 50,847,826.59 in 2023, reflecting a decrease of approximately 12%[16]. Other Financial Metrics - The weighted average return on net assets was -0.35%, a decrease of 6.35 percentage points compared to the previous year[3]. - The company's inventory stood at CNY 83,416,622.65, slightly down from CNY 84,322,671.95 in the previous quarter[13]. - Accounts receivable increased to RMB 38.07 million from RMB 35.18 million[12]. - Other receivables rose significantly to RMB 18.00 million from RMB 8.69 million[12]. - The company reported a significant increase in credit impairment losses of -3,316,612.29 RMB in the third quarter of 2024, compared to 3,596,930.03 RMB in the same period of 2023[17]. - The company reported a net investment income of CNY 21,965,359.14 for the first three quarters of 2024, compared to CNY 13,899,996.37 in the same period of 2023, representing an increase of about 58%[16]. - The company’s long-term borrowings increased to CNY 96,926,196.94 from CNY 37,072,501.11, indicating a significant rise in leverage[14].